As GLP-1 receptor agonists and other obesity pharmacotherapies become increasingly prescribed, clinicians need practical, evidence-based tools to guide nutritional counseling. Dietary quality becomes especially critical when caloric intake is reduced — nutritional needs must still be fully met.
Understanding the Nutritional Impact of Obesity Medications
Obesity affects an estimated 90 million people in the United States. Between 1999 and 2020, adult obesity rates rose from 30.5% to 41.9%, with severe obesity increasing from 4.7% to 9.2%. Originally developed for type 2 diabetes management, GLP-1 receptor agonists have emerged as highly effective pharmacologic interventions for obesity and related cardiometabolic comorbidities.
While these agents offer substantial benefits, their success depends on proactive nutritional management. Common challenges include gastrointestinal side effects, potential micronutrient deficiencies from reduced intake, loss of lean body mass, and the risk of weight regain following treatment cessation.
Key clinical consideration
Early recognition and management of persistent or severe gastrointestinal symptoms enables clinicians to take preventive action, reducing the risk of complications and improving treatment adherence.
Key Nutrition Recommendations During Therapy
The 2025 Updated AACE Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease, recommends prioritizing nutrient density to support patient health and treatment outcomes. The following areas are central to counseling patients on obesity pharmacotherapy.
Lean Protein
Target 1.2–1.5 g/kg/day to preserve lean body mass. Emphasize poultry, fish, legumes, and low-fat dairy.
Nutrient-Dense Carbohydrates
Prioritize vegetables, beans/pulses, and fruits. Minimize refined or processed carbohydrate sources.
Micronutrient Supplementation
Consider daily multivitamin with iron and calcium. Monitor B12, vitamin D, and folate per clinical history.
Fiber & Hydration
Gradually increase fiber to minimize GI side effects. Maintain adequate daily fluid intake throughout therapy.
Resistance Training & Physical Activity
Adequate protein intake alone may not fully preserve skeletal muscle mass during weight loss. Nutritional strategies should be combined with regular resistance training and physical activity to optimize preservation of lean body mass, physical function, and overall body composition during pharmacologically assisted weight loss.
Flexible use of meal replacements may also be appropriate and can help patients meet nutritional targets when appetite is significantly reduced. Personalization of dietary recommendations to align with individual lifestyles and preexisting nutritional risks is a key theme in patient communication.
Counseling Strategies for Common Medication Effects
Gastrointestinal symptoms are among the most frequently reported challenges during GLP-1 therapy. Proactive counseling can significantly improve patient tolerance and treatment adherence.
- Eat slowly and mindfully; reduce portion sizes
- Avoid high-fat or known trigger foods
- Track foods that worsen symptoms
- Shift to 4–5 smaller meals per day
- Prioritize protein at every meal
- Avoid large fluid intake with meals
- Gradually increase dietary fiber intake
- Maintain adequate daily hydration
- Encourage routine physical activity
- Temporarily reduce high-fiber foods
- Avoid fatty, greasy, or spicy meals
- Maintain electrolyte intake & hydration
- Maintain structured mealtimes even without hunger cues
- Use nutrient-dense, calorie-efficient foods
- Monitor for signs of nutritional insufficiency
Micronutrient Monitoring & Long-Term Considerations
As patients sustain reduced caloric intake over time, the risk for micronutrient deficiencies increases. Monitoring should be proactive and ongoing — not reactive. Iron and calcium represent priority supplementation targets.
Clinicians should conduct periodic laboratory assessments to identify subclinical deficiencies. Laboratory monitoring should be individualized and guided by patient-specific risk factors, including advanced age, prolonged reductions in caloric intake, restrictive dietary patterns, pre-existing deficiencies, and significant weight loss over time. Vitamin D, B12, folate, iron, and other micronutrients may warrant monitoring depending on clinical history and dietary patterns.
Weight regain following treatment cessation is a significant concern. Given the chronic and relapsing nature of obesity, nutritional counseling should not be viewed as an adjunct to pharmacotherapy, but rather as a foundational component of care. Nutritional support should begin at treatment initiation and continue throughout active treatment, maintenance, and any planned or unplanned discontinuation to support long-term outcomes and minimize the risk of weight regain.
The Role of Multidisciplinary Collaboration
Nutrition counseling and monitoring for patients on obesity pharmacotherapy should be ongoing and ideally involve a coordinated care team. A qualitative study published in 2024 found that initiating conversations that set honest expectations with patients is crucial.
Building the Right Care Team
Personalizing recommendations to align with individual lifestyles and preexisting nutritional risks was a central theme in effective patient communication. The care team may include:
Thank you to our AACE member volunteer for developing this guide: Dr. Md. Salman Hossain, MBBS, MD
References
- Hales CM, et al. Prevalence of Obesity and Severe Obesity Among Adults. NCHS Data Brief. 2020.
- CDC. Adult Obesity Facts. Centers for Disease Control and Prevention. 2023.
- Flegal KM, et al. Trends in Obesity Among Adults in the United States. JAMA. 2016.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021.
- AACE Consensus Statement: Algorithm for Evaluation and Treatment of Adults with Obesity — 2026 Update.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024.
- Garvey WT, et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016.
- Wharton S, et al. Obesity in Adults: A Clinical Practice Guideline. CMAJ. 2020.
- Saxon DR, et al. Antiobesity Medication Use in US Adults. J Clin Endocrinol Metab. 2021.
- Pilitsi E, et al. Pharmacotherapy of Obesity. Metabolism. 2019.
- Blonde L, et al. AACE Clinical Practice Guideline. Endocr Pract. 2022.
- Ryan DH, Lingvay I, et al. Long-term Weight Loss Effects of Semaglutide. Nat Med. 2023.
Support provided in part by:
